// App-Quantinova.ai

e19138 : Healthcare resource use (HRU) in men with metastatic castration sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT) only or no treatment in the United States (US).

Researchers

Presenter

  • Xuehua Ke

Principal Investigators

  • Marie-Hlne Lafeuille

  • Hela Romdhani

  • Frederic Kinkead

  • Peter St. John Francis

  • Denise D'Andrea

  • Charles J. Ryan

  • Stephen J. Freedland

Medical Centers

  • Janssen Scientific Affairs, Horsham, PA

  • Analysis Group, Inc., Montreal, QC, Canada

  • Janssen Pharmaceuticals, Raritan, NJ

  • Vascular Biology Center, Division of Hematology, Oncology & Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN

  • Division of Urology, Department of Surgery, Cedars-Sinai Medical Center

  • Urology Section, Durham VA Medical Center, Durham, NC, Los Angeles, CA

Locations

  • United States

  • Canada

Companies

  • Analysis Group, Inc.

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved